A V Kaisary
Overview
Explore the profile of A V Kaisary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kaisary A, Iversen P, Tyrrell C, Carroll K, Morris T
Prostate Cancer Prostatic Dis
. 2002 Dec;
4(4):196-203.
PMID: 12497018
Castration is the most widely used form of androgen ablation employed in the treatment of metastatic (M1) prostate cancer. Non-steroidal antiandrogen monotherapy is a potential alternative treatment option for men...
12.
Amobi N, Guillebaud J, Kaisary A, Turner E, Smith I
Br J Pharmacol
. 2002 Apr;
136(1):127-35.
PMID: 11976277
The effects of irreversible alpha1-adrenoceptor antagonists, SZL-49 (an alkylating analogue of prazosin), dibenamine and benextramine on contractions to noradrenaline (NA) in longitudinal and circular muscle of human epididymal vas deferens...
13.
Kaisary A
Drugs Aging
. 2001 Feb;
17(5):331-7.
PMID: 11190414
Palliation of patients with metastatic prostate cancer is based primarily on offering a form of androgen ablation. Each therapeutic modality has advantages and disadvantages. The decision with regards to the...
14.
Iversen P, Tyrrell C, Kaisary A, Anderson J, van Poppel H, Tammela T, et al.
J Urol
. 2000 Oct;
164(5):1579-82.
PMID: 11025708
Purpose: Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in...
15.
Hamilton J, Stewart L, Ajayi L, Gray I, Gray N, Roberts K, et al.
Br J Cancer
. 2000 May;
82(10):1671-6.
PMID: 10817502
PTEN, a putative tumour suppressor gene associated with prostate and other cancers, is known to be located within the chromosomal region 10q23.3. Transcription of the PTEN gives rise to multiple...
16.
Kaisary A, Bowsher W, Gillatt D, Anderson J, Malone P, Imbimbo B
J Urol
. 1999 Nov;
162(6):2019-23.
PMID: 10569560
Purpose: We evaluate the pharmacodynamics, pharmacokinetics and tolerability of a sustained release depot formulation of avorelin, a new potent super agonist of luteinizing hormone-releasing hormone receptors, in patients with prostate...
17.
Tyrrell C, Kaisary A, Iversen P, Anderson J, Baert L, Tammela T, et al.
Eur Urol
. 1998 Jun;
33(5):447-56.
PMID: 9643663
Objectives: To evaluate the efficacy and tolerability of 'Casodex' monotherapy (150 mg daily) for metastatic and locally advanced prostate cancer. Methods: A total of 1,453 patients with either confirmed metastatic...
18.
Sandhu S, Kaisary A
Postgrad Med J
. 1998 Mar;
73(865):691-6.
PMID: 9519179
The incidence and prevalence of prostate cancer is increasing. A number of aetiological factors including age, race, family history and diet have been implicated. The majority of patients present with...
19.
Iversen P, Tyrrell C, Kaisary A, Anderson J, Baert L, Tammela T, et al.
Urology
. 1998 Mar;
51(3):389-96.
PMID: 9510340
Objectives: To compare the efficacy, tolerability, and quality of life benefits of bicalutamide (Casodex) 150-mg/day monotherapy and castration in previously untreated nonmetastatic (M0) advanced prostate cancer. Methods: A total of...
20.
Wilson C, Sandhu S, Kaisary A
Br J Urol
. 1998 Jan;
80(6):915-7.
PMID: 9439409
Objective: To determine if the use of a catheter-valve rather than a standard drainage system decreases the morbidity associated with the use of a long-term catheter. Patients And Methods: One...